Unibest
← Back to patent-cliff list

Foxy-5

Tier C — Watch / trade

Foxy-5

Wntresearch Ab
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:WNT5A

Indications (approved):Colon cancer, Prostate cancer, Metastatic breast cancer, Colorectal cancer

Regional status

US
-
EU
Phase II
2019-04-12
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 12.3 g (Foxy-5)
Foxy-5-00171989-18-9Foxy-5-0022748-02-9Foxy-5-003200936-59-0Foxy-5-0042412026-00-5Foxy-5-0052412025-97-7Foxy-5-0062412026-01-6Foxy-5-0072412025-98-8Foxy-5-0082412025-99-9API · Foxy-5
CodeCAS No.Intermediate
Foxy-5-00171989-18-9(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid
Foxy-5-0022748-02-9tert-butyl L-leucinate hydrochloride
Foxy-5-003200936-59-0tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)-5-oxopentanoate
Foxy-5-0042412026-00-5tert-butyl (5R,8S,11S)-8-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoren-9-yl)-11-isobutyl-3,6,9-trioxo-5-((tritylthio)methyl)-2-oxa-4,7,10-triazadodecan-12-oate
Foxy-5-0052412025-97-7tert-butyl (8R,11S,14S)-11-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoren-9-yl)-14-isobutyl-3,6,9,12-tetraoxo-8-((tritylthio)methyl)-2-oxa-4,7,10,13-tetraazapentadecan-15-oate
Foxy-5-0062412026-01-6di-tert-butyl (2S,5S,8R,14S)-14-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(3-(tert-butoxy)-3-oxopropyl)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate
Foxy-5-0072412025-98-8di-tert-butyl (2S,5S,8R,14S)-14-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methylthio)butanamido)-5-(3-(tert-butoxy)-3-oxopropyl)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate
Foxy-5-0082412025-99-9di-tert-butyl (2S,5S,8R,14S)-5-(3-(tert-butoxy)-3-oxopropyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate

Frequently asked questions

What are the approved indications of Foxy-5?

Approved indications include: Colon cancer, Prostate cancer, Metastatic breast cancer, Colorectal cancer.

When does the Foxy-5 patent expire?

No public expiry year is available for Foxy-5 yet; this page updates once verified.

How many synthesis routes are recorded for Foxy-5?

1 synthesis routes are recorded; the shortest is 7 steps with 12.3 g (Foxy-5) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Foxy-5 intermediates?

All intermediates in Foxy-5 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Foxy-5 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-08